Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

A first-of-its-kind treatment to slow the symptoms of early Alzheimer's disease has been approved for use in Australia.

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify patients with DYPD gene variants who may be at ...

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

If we haven't been touched by Alzheimer's directly, we know someone who has. In fact, more than 7 million Americans aged 65 ...

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

The stock market volatility will only worsen as the U.S. continues to threaten its trade partners with tariffs. Investors do ...

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the ...

Donanemab (Kisunla) is the first new drug approved in Australia for the treatment of mild cognitive impairment in 25 years.